CRYSVITA (burosumab-twza)

10 mg/mL subcutaneous solution

• Inject 1 mg/kg by subcutaneous route every 4 weeks (round to nearest 10 mg up to max dose of 90 mg) ; maximum of 1.5 ml per injection site

20 mg/mL subcutaneous solution

• Inject 1 mg/kg by subcutaneous route every 4 weeks (round to nearest 10 mg up to max dose of 90 mg) ; maximum of 1.5 ml per injection site

30 mg/mL subcutaneous solution

• Inject 1 mg/kg by subcutaneous route every 4 weeks (round to nearest 10 mg up to max dose of 90 mg) ; maximum of 1.5 ml per injection site

FGf23-related hypophosphatemia in TIO due to PMT

• Inject 1 mg/kg by subcutaneous route every 4 weeks (round to nearest 10 mg up to max dose of 180 mg) ; maximum of 1.5 ml per injection site

• Inject 1.5 mg/kg by subcutaneous route every 4 weeks (round to nearest 10 mg up to max dose of 180 mg) ; max of 1.5 ml per injection site

• Inject 2 mg/kg by subcutaneous route every 4 weeks (round to nearest 10 mg up to max dose of 180 mg) ; maximum of 1.5 ml per injection site

• Inject 0.5 mg/kg by subcutaneous route every 2 weeks (round to nearest 10 mg up to max dose of 180 mg) ; max of 1.5 ml per injection site

• Inject 0.75 mg/kg by subcutaneous route every 2 weeks (round to nearest 10 mg up to max dose of 180 mg) ; max of 1.5 ml per injection site

• Inject 1.5 mg/kg by subcutaneous route every 2 weeks (round to nearest 10 mg up to max dose of 180 mg) ; max of 1.5 ml per injection site

• Inject 1 mg/kg by subcutaneous route every 2 weeks (round to nearest 10 mg up to max dose of 180 mg) ; maximum of 1.5 ml per injection site

• Inject 2 mg/kg by subcutaneous route every 2 weeks (round to nearest 10 mg up to max dose of 180 mg) ; maximum of 1.5 ml per injection site

X-linked hypophosphatemic osteomalacia

• Inject 1 mg/kg by subcutaneous route every 4 weeks (round to nearest 10 mg up to max dose of 90 mg) ; maximum of 1.5 ml per injection site